• Je něco špatně v tomto záznamu ?

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

JW. Goldman, M. Dvorkin, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, MJ. Hochmair, M. Özgüroğlu, JH. Ji, MC. Garassino, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Każarnowicz, G. Losonczy, NV....

. 2021 ; 22 (1) : 51-65. [pub] 20201204

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011673
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 33285097
DOI 10.1016/s1470-2045(20)30539-8
Knihovny.cz E-zdroje

BACKGROUND: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone. METHODS: CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment-naive, histologically or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-response system to receive intravenous durvalumab plus tremelimumab plus platinum-etoposide, durvalumab plus platinum-etoposide, or platinum-etoposide alone. In all groups, patients received etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m2 on day 1 of each cycle. Patients in the platinum-etoposide group received up to six cycles of platinum-etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum-etoposide versus platinum-etoposide and for durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872. FINDINGS: Between March 27, 2017, and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum-etoposide, 268 to durvalumab plus platinum-etoposide, and 269 to platinum-etoposide). As of Jan 27, 2020, the median follow-up was 25·1 months (IQR 22·3-27·9). Durvalumab plus tremelimumab plus platinum-etoposide was not associated with a significant improvement in overall survival versus platinum-etoposide (hazard ratio [HR] 0·82 [95% CI 0·68-1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6-12·0) versus 10·5 months (9·3-11·2). Durvalumab plus platinum-etoposide showed sustained improvement in overall survival versus platinum-etoposide (HR 0·75 [95% CI 0·62-0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3-14·7) versus 10·5 months (9·3-11·2). The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum-etoposide group, and 88 [33%] of 266 patients in the platinum-etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). Any-cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 85 (32%) in the durvalumab plus platinum-etoposide group, and 97 (36%) in the platinum-etoposide group. Treatment-related deaths occurred in 12 (5%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum-etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in the platinum-etoposide group (pancytopenia and thrombocytopenia [n=1 each]). INTERPRETATION: First-line durvalumab plus platinum-etoposide showed sustained overall survival improvement versus platinum-etoposide but the addition of tremelimumab to durvalumab plus platinum-etoposide did not significantly improve outcomes versus platinum-etoposide. These results support the use of durvalumab plus platinum-etoposide as a new standard of care for the first-line treatment of ES-SCLC. FUNDING: AstraZeneca.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011673
003      
CZ-PrNML
005      
20230109125819.0
007      
ta
008      
210420s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(20)30539-8 $2 doi
035    __
$a (PubMed)33285097
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Goldman, Jonathan W $u David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA
245    10
$a Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial / $c JW. Goldman, M. Dvorkin, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, MJ. Hochmair, M. Özgüroğlu, JH. Ji, MC. Garassino, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Każarnowicz, G. Losonczy, NV. Conev, J. Armstrong, N. Byrne, P. Thiyagarajah, H. Jiang, L. Paz-Ares, CASPIAN investigators
520    9_
$a BACKGROUND: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone. METHODS: CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment-naive, histologically or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-response system to receive intravenous durvalumab plus tremelimumab plus platinum-etoposide, durvalumab plus platinum-etoposide, or platinum-etoposide alone. In all groups, patients received etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m2 on day 1 of each cycle. Patients in the platinum-etoposide group received up to six cycles of platinum-etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum-etoposide versus platinum-etoposide and for durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872. FINDINGS: Between March 27, 2017, and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum-etoposide, 268 to durvalumab plus platinum-etoposide, and 269 to platinum-etoposide). As of Jan 27, 2020, the median follow-up was 25·1 months (IQR 22·3-27·9). Durvalumab plus tremelimumab plus platinum-etoposide was not associated with a significant improvement in overall survival versus platinum-etoposide (hazard ratio [HR] 0·82 [95% CI 0·68-1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6-12·0) versus 10·5 months (9·3-11·2). Durvalumab plus platinum-etoposide showed sustained improvement in overall survival versus platinum-etoposide (HR 0·75 [95% CI 0·62-0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3-14·7) versus 10·5 months (9·3-11·2). The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum-etoposide group, and 88 [33%] of 266 patients in the platinum-etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). Any-cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 85 (32%) in the durvalumab plus platinum-etoposide group, and 97 (36%) in the platinum-etoposide group. Treatment-related deaths occurred in 12 (5%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum-etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in the platinum-etoposide group (pancytopenia and thrombocytopenia [n=1 each]). INTERPRETATION: First-line durvalumab plus platinum-etoposide showed sustained overall survival improvement versus platinum-etoposide but the addition of tremelimumab to durvalumab plus platinum-etoposide did not significantly improve outcomes versus platinum-etoposide. These results support the use of durvalumab plus platinum-etoposide as a new standard of care for the first-line treatment of ES-SCLC. FUNDING: AstraZeneca.
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a karboplatina $x aplikace a dávkování $x škodlivé účinky $7 D016190
650    _2
$a cisplatina $x aplikace a dávkování $x škodlivé účinky $7 D002945
650    _2
$a progrese nemoci $7 D018450
650    _2
$a etoposid $x aplikace a dávkování $x škodlivé účinky $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x mortalita $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a malobuněčný karcinom plic $x farmakoterapie $x mortalita $x patologie $7 D055752
650    _2
$a časové faktory $7 D013997
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dvorkin, Mikhail $u BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia
700    1_
$a Chen, Yuanbin $u Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA
700    1_
$a Reinmuth, Niels $u Asklepios Lung Clinic, Munich-Gauting, Germany
700    1_
$a Hotta, Katsuyuki $u Okayama University Hospital, Okayama, Japan
700    1_
$a Trukhin, Dmytro $u Odessa Regional Oncological Dispensary, Odessa, Ukraine
700    1_
$a Statsenko, Galina $u Omsk Regional Cancer Centre, Omsk, Russia
700    1_
$a Hochmair, Maximilian J $u Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria
700    1_
$a Özgüroğlu, Mustafa $u Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
700    1_
$a Ji, Jun Ho $u Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea
700    1_
$a Garassino, Marina $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy $7 xx0280337
700    1_
$a Voitko, Oleksandr $u Kyiv City Clinical Oncological Centre, Kiev, Ukraine
700    1_
$a Poltoratskiy, Artem $u Petrov Research Institute of Oncology, St Petersburg, Russia
700    1_
$a Ponce, Santiago $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain
700    1_
$a Verderame, Francesco $u Azienda Ospedaliera Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy
700    1_
$a Havel, Libor $u Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Bondarenko, Igor $u Dnipropetrovsk Medical Academy, Dnipro, Ukraine
700    1_
$a Każarnowicz, Andrzej $u Tuberculosis and Lung Disease Hospital, Olsztyn, Poland
700    1_
$a Losonczy, György $u Department of Pulmonology, Semmelweis University, Budapest, Hungary
700    1_
$a Conev, Nikolay V $u Clinic of Medical Oncology, University Multiprofile Hospital for Active Treatment St Marina, Varna, Bulgaria
700    1_
$a Armstrong, Jon $u AstraZeneca, Cambridge, UK
700    1_
$a Byrne, Natalie $u AstraZeneca, Cambridge, UK
700    1_
$a Thiyagarajah, Piruntha $u AstraZeneca, Cambridge, UK
700    1_
$a Jiang, Haiyi $u AstraZeneca, Gaithersburg, MD, USA
700    1_
$a Paz-Ares, Luis $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic address: lpazaresr@seom.org
710    2_
$a CASPIAN investigators
773    0_
$w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 22, č. 1 (2021), s. 51-65
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33285097 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20230109125817 $b ABA008
999    __
$a ok $b bmc $g 1650137 $s 1132052
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 1 $d 51-65 $e 20201204 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace